Press Releases - News for BioHouston

The top 50 press releases in our database are displayed below.

49 Record(s) Found. Displaying Page 1:

1 2 3 [Next >>]

Dedication of UTMB’s Galveston National Laboratory
Release Date: 28-Oct-08 Author or Contact: Category: Recent News
GALVESTON, Texas — After more than five years of careful planning, design and construction, UTMB’s Galveston National Laboratory is complete and the facility will be formally dedicated on Tuesday, Nov. 11. “The GNL brings the focus on global health research to Galveston — and that’s something our local community can be proud of. This facility is indeed a national resource,” said Dr. Stanley M. Lemon, principal investigator of the ...
Click to read Dedication of UTMB’s Galveston National Laboratory

KCI Receives FDA Clearance for its LifeCell Tissue Matrix for the Management of Wounds Utilizing Proprietary Strattice(R) Technology
Release Date: 14-Oct-08 Author or Contact: Category: Recent News
SAN ANTONIO--(BUSINESS WIRE)-- Kinetic Concepts, Inc. (NYSE: KCI) today announced that it has received FDA 510(k) clearance for its LifeCell Tissue Matrix for the management of chronic, trauma, surgical and other acute wounds. The product utilizes the company's proprietary Strattice(R) technology, which is a sterile reconstructive tissue matrix that supports tissue regeneration. The Strattice technology is a porcine-based, acellular ...
Click to read KCI Receives FDA Clearance for its LifeCell Tissue Matrix for the Management of Wounds Utilizing Proprietary Strattice(R) Technology

Lexicon to Present Clinical Data for LX2931, an Investigational New Drug for Rheumatoid Arthritis
Release Date: 14-Oct-08 Author or Contact: Category: Recent News
The Woodlands, Texas, October 14, 2008 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that the company will be presenting initial Phase 1 clinical trial results for LX2931, an orally-delivered, small molecule drug candidate for the treatment of rheumatoid arthritis and other autoimmune conditions at the annual meeting of ...
Click to read Lexicon to Present Clinical Data for LX2931, an Investigational New Drug for Rheumatoid Arthritis

Synthecon Receives $738,000 Phase II Grant From The National Institutes Of Health (NIH) To Improve Islet Transplantation Techniques To Treat Type 1 Diabetes
Release Date: 13-Oct-08 Author or Contact: Bill Anderson Category: Recent News
HOUSTON, TX; August 26, 2008: Synthecon, Inc., a Johnson Space Center spin-off, announced today that the Company has received notice from the National Institutes of Health (NIH) that its $738,000 Phase II Grant proposal to improve the transplantation of pancreatic islets in type 1 diabetic patients has been approved for funding. Synthecon’s Phase II Grant follows successful completion of a Phase I Grant from the NIH, which developed improved ...
Click to read Synthecon Receives $738,000 Phase II Grant From The National Institutes Of Health (NIH) To Improve Islet Transplantation Techniques To Treat Type 1 Diabetes

Power3 Medical Products in Collaboration with StemTroniX, Inc., to Identify and Monitor Autologous Adult Stem Cells for Use in Stem Cell Therapy using Protein Biomarkers
Release Date: 9-Oct-08 Author or Contact: Category: Recent News
HOUSTON--(BUSINESS WIRE)--Power3 Medical Products, Inc. (OTCBB:PWRM - News), (www.power3medical.com), today announced that the company has executed a Letter of Intent with StemTroniX, Inc., a Texas based Stem Cell Therapy Company that specializes in research, exploration and consolidation of stem cell technologies for use in Autologous Adult Stem Cell Therapy’s and Transplantations. “Power3 Medical is excited ...
Click to read Power3 Medical Products in Collaboration with StemTroniX, Inc., to Identify and Monitor Autologous Adult Stem Cells for Use in Stem Cell Therapy using Protein Biomarkers

eCardio Launches the eVolution(SM)
Release Date: 8-Oct-08 Author or Contact: Category: Recent News
Extended cardiac monitoring system provides instant and accurate patient information through automated data transmissions THE WOODLANDS, Texas, Oct. 8 /PRNewswire/ -- eCardio Diagnostics, LLC announced the launch of the eVolution(SM), a single-component cardiac monitoring system that provides instant and accurate patient information through automated data transmissions. "The eVolution(SM) is the next leap ...
Click to read eCardio Launches the eVolution(SM)

Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody
Release Date: 2-Oct-08 Author or Contact: Category: Recent News
Data Indicate Dual Modes of Action and Synergy with Chemotherapy DALLAS, Oct. 2 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) presented data this week from preclinical studies on Angiolix showing that by blocking lactadherin, Angiolix has both an anti-angiogenic effect as well as a direct anti-proliferative effect on tumors themselves. In preclinical models of human breast cancer ...
Click to read Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody

ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver
Release Date: 30-Sep-08 Author or Contact:
ADDISON, Texas, Sept. 30 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today announced that it has filed a 510k application with the United States Food and Drug Administration (FDA) for Altrazeal(TM) Silver. Preclinical studies conducted to support the filing have shown that superior healing rates in numerous porcine wound models have been achieved relative to competitive silver dressings. Additionally, in ...
Click to read ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver

Repros Therapeutics Inc. Announces $15.6 Million Financing
Release Date: 29-Sep-08 Author or Contact: Tim Graves Category: Recent News
Repros Therapeutics Inc. Announces $15.6 Million Financing Repros Will Add Two New Directors to its Board of Directors THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today announces that it has entered into definitive agreements to sell an aggregate of 2.4 million shares of its common stock at a purchase price of $6.50 per share for an aggregate $15.6 million financing under its previously announced shelf ...
Click to read Repros Therapeutics Inc. Announces $15.6 Million Financing

UT Southwestern Medical Center pushes forward with biotech park
Release Date: 18-Sep-08 Author or Contact: Tim Graves
The University of Texas Southwestern Medical Center at Dallas is setting the stage for health care innovation in the Dallas-Fort Worth area with a new biotech park -- the BioCenter at Southwestern Medical District. The 13-acre park, purchased from the City of Dallas for $4.1 million, will eventually consist of four buildings that will provide up to 500,000 square feet of lab, office and research space. It has one building slated to open in ...
Click to read UT Southwestern Medical Center pushes forward with biotech park

ENTrigue Surgical, Inc. Announces Product Commercialization
Release Date: 18-Sep-08 Author or Contact: Tim Graves Category: Recent News
SAN ANTONIO, Sept. 18 /PRNewswire/ -- ENTrigue Surgical, Inc. announces the commercial release of its initial SerpENT(TM) Articulating Instruments, the first of several innovative solutions for ENT (Ear, Nose, and Throat) surgery. The SerpENT(TM) instruments utilize a patented technology that enables instruments to bend around corners, resulting in less invasive and more efficient surgical procedures. The Company plans to commercialize several ...
Click to read ENTrigue Surgical, Inc. Announces Product Commercialization

Azaya Therapeutics Licenses Promising Treatment for Head and Neck Cancers
Release Date: 14-Sep-08 Author or Contact: Tim Graves Category: Recent News
San Antonio – Azaya Therapeutics, Inc., announced today that it has signed a licensing agreement to further develop a breakthrough technology that uses liposomes to deliver radiation through direct injection into head and neck tumors, shrinking the tumor, delaying recurrence and avoiding the collateral tissue damage that often accompanies all other forms of radiation therapy. The company plans to begin a phase I clinical trial in early 2010. ...
Click to read Azaya Therapeutics Licenses Promising Treatment for Head and Neck Cancers

HOUSTON REGION BIOTECH/LIFE SCIENCE GROWTH IN DOUBLE DIGITS
Release Date: 11-Sep-08 Author or Contact: Tim Graves Category: Recent News
Houston Region Biotech/Life Science Growth in Double Digits $13 Billion in Research Funding Now Producing Increases in Products, Licenses, Companies & Jobs: BioHouston HOUSTON, Sept. 11, 2008 – More than $13 billion in basic research funding over the past nine years is now producing double-digit annual increases in the numbers of technology licenses, new company start-ups and new biotech and life science patent applications in ...
Click to read HOUSTON REGION BIOTECH/LIFE SCIENCE GROWTH IN DOUBLE DIGITS

Power3 Medical Products, Inc. Appoints Helen Park as Interim Chief Executive Officer
Release Date: 10-Sep-08 Author or Contact: Tim Graves Category: Recent News
HOUSTON--(BUSINESS WIRE)--Power3 Medical Products, Inc. (OTCBB:PWRM - News), a leading proteomics company specializing in the development and commercialization of diagnostic blood tests for early detection of breast cancer and neurodegenerative diseases, has appointed Helen Park as the company’s interim Chief Executive Officer, effective September 7, 2008. Mr. Steven B. Rash resigned as Chief Executive Officer and Chairman of Power3. Mr. Rash’s ...
Click to read Power3 Medical Products, Inc. Appoints Helen Park as Interim Chief Executive Officer

Manufacturer of Innovative Zeno Acne Treatment Device Announces Corporate Name Change
Release Date: 9-Sep-08 Author or Contact: Tim Graves Category: Recent News
HOUSTON, Sept. 9 /PRNewswire/ -- Tyrell, Inc., the company behind the Zeno family of acne treatment devices, announced today that they have changed their name to Zeno Corporation. "We initiated the name change in an effort to provide clarity as to who and what we are," said Walter Klemp, CEO of Zeno Corporation. "The leadership of the company and our board of directors recognized that our new name more closely aligns our corporate ...
Click to read Manufacturer of Innovative Zeno Acne Treatment Device Announces Corporate Name Change

Introgen Receives Notice ADVEXIN(R) U.S. BLA Not Sufficiently Complete to File
Release Date: 2-Sep-08 Author or Contact: Tim Graves Category: Recent News
AUSTIN, Texas, Sep 02, 2008 (BUSINESS WIRE) -- Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today announced that the United States Food and Drug Administration (FDA) notified the Company that its Biologics License Application (BLA) for ADVEXIN(R) (p53 tumor suppressor therapy) for the treatment of recurrent, refractory squamous cell carcinoma of the head and ...
Click to read Introgen Receives Notice ADVEXIN(R) U.S. BLA Not Sufficiently Complete to File

UT to dedicate new biomedical engineering building
Release Date: 25-Aug-08 Author or Contact: Tim Graves Category: Recent News
University of Texas officials will dedicate the school’s new $55 million Biomedical Engineering Building this week. The 141,000-square-foot laboratory and research building on Dean Keaton Road is debuting in time for the fall semester. University President William Powers Jr. and Ben Streetman, dean of the Cockrell School of Engineering will be among those on hand to dedicate the building at a ceremony at 2 p.m. on Thursday. University ...
Click to read UT to dedicate new biomedical engineering building

Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
Release Date: 18-Aug-08 Author or Contact:
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) and Milestone Biosciences, LLC ("Milestone") today announced the signing of a definitive license agreement under which Milestone will market Access' proprietary product MuGard(TM) in the United States and Canada. Milestone is a company recently started by former executives and sales representatives of companies with an established commercial presence in oncology, including MGI ...
Click to read Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America

Repros Therapeutics Inc. Provides Update for US Phase II Endometriosis Study and Completion of QT Interval Dose Selection Screen
Release Date: 18-Aug-08 Author or Contact: Joseph Podolski
Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that based on the robust efficacy demonstrated by Proellex® in the interim assessment of the Company’s Phase II endometriosis study, there are sufficient patients currently enrolled to provide for adequate power calculations for the Phase III endometriosis trials. Because of the profound effect noted in this interim analysis, the Company has decided to curtail further patient ...
Click to read Repros Therapeutics Inc. Provides Update for US Phase II Endometriosis Study and Completion of QT Interval Dose Selection Screen

Introgen's ADVEXIN(R) MAA Accepted for Review by European Medicines Agency
Release Date: 18-Aug-08 Author or Contact: Channing Burke
Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, and its subsidiary Gendux Molecular Limited, today announced that the European Medicines Agency (EMEA) has accepted for review the company's Marketing Authrorization Application (MAA) for ADVEXIN(R) (p53 tumor suppressor therapy) for the treatment of recurrent, refractory squamous cell carcinoma of the head and neck. ADVEXIN is an innovative gene ...
Click to read Introgen's ADVEXIN(R) MAA Accepted for Review by European Medicines Agency

1 2 3 [Next >>]

Contact Us | Site Map |

| OPML | Search This Site | Home
Schipul Web Design | Tendenci® Content Management Software | Privacy | Terms and Conditions